Trials / Conditions / Malignant Lymphoma

Malignant Lymphoma

26 registered clinical trials studyying Malignant Lymphoma — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Completed	EchoTip AcuCore Post-Market Clinical Study NCT06358001	Cook Research Incorporated	—
Not Yet Recruiting	A Randomized, Comparative, Double-blind Trial of Pentaisomaltose and Dimethyl Sulphoxide for Cryoprotection of NCT05545202	Pharmacosmos A/S	Phase 4
Active Not Recruiting	Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Child NCT06475820	Federal Research Institute of Pediatric Hematology, Oncology and Immunology	Phase 2 / Phase 3
Completed	A Real-World Study of COVID-19 Infection in Patients With Malignant Lymphomas Participating in Clinical Trials NCT05827341	Sun Yat-sen University	—
Active Not Recruiting	Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibito NCT05515029	Federal Research Institute of Pediatric Hematology, Oncology and Immunology	Phase 3
Completed	Quality Assurance on Anemia Management in Patients With Solid Tumors and Malignant Lymphoma NCT05190263	AIO-Studien-gGmbH	—
Recruiting	CPAP or BiPAP for Motion Mitigation During Radiotherapy NCT04986293	University Medical Center Groningen	N/A
Completed	Impact of COVID-19 After Autologous Hematopoietic Stem Cell Transplantation in Sweden NCT04760184	Uppsala University	—
Withdrawn	HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation NCT04464889	Medigene AG	Phase 1
Unknown	Lean Body Mass and Side Effects in Patients With Lymphoma NCT04698616	Jens Rikardt Andersen	—
Completed	TEAM (Thiotepa, Etoposide, Cytosar, Melphalan ) for AutoSCT in Lymphoma NCT03346096	Sheba Medical Center	Phase 2
Completed	Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Toripalimab for Patients With Recurrent Malignant NCT03316144	Shanghai Junshi Bioscience Co., Ltd.	Phase 1
Unknown	Phase 1/2 Study of the Combination of Pixantrone, Etoposide, Bendamustine and, in CD20 Positive Tumors, Rituxi NCT02678299	University of Aarhus	Phase 1 / Phase 2
Unknown	Emergence of Chemotherapy Related Hyperglycemia in nOn-diabetic Patients NCT03062072	National Cancer Center, Korea	—
Unknown	Phase I Study of Mitoxantrone Hydrochloride Liposome Injection NCT02131688	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	Phase 1
Completed	p-AKT Expression on Clinical Outcomes in Malignant Lymphoma NCT01789060	Samsung Medical Center	—
Completed	Global Phase1 Study to Assess the Safety and Tolerability of AZD1208 in Advanced Solid Tumors and Malignant Ly NCT01588548	AstraZeneca	Phase 1
Completed	Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant NCT01473095	ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)	Phase 1
Completed	Influence of Rifampin on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer NCT01324323	Celgene	Phase 1
Completed	Influence of Ketoconazole on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer NCT01324310	Celgene	Phase 1
Completed	Can Treatment With Bismuth Reduce Toxicity to Chemotherapy and Radiotherapy? NCT00892502	Copenhagen University Hospital at Herlev	N/A
Completed	Interest of a Systematic One-year Monitoring by 18F-FDG PET-CT NCT04464590	University Hospital, Brest	—
Completed	Whole-body Magnetic Resonance Imaging (MRI) for Staging Malignant Lymphomas NCT00685997	UMC Utrecht	—
Completed	T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies NCT00683046	University of Chicago	Phase 2
Completed	Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies NCT01499147	University of Illinois at Chicago	N/A
Terminated	Stem Cell Factor (SCF) Priming of Haematopoietic Stem Cell Grafts in Malignant Lymphoma NCT01016795	Aalborg University Hospital	Phase 2